SERTAD2: A Potential Drug Target and Biomarker (G9792)

Target Name: SERTAD2

NCBI ID: G9792

SERTAD2

SERTAD2: A Potential Drug Target and Biomarker

SERTAD2 (SERTA domain-containing protein 2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a significant amount of research in recent years.

The SERTAD2 protein is a member of the SERTAD family, which is known for its role in various cellular processes, including cell signaling, DNA replication, and apoptosis. SERTAD2 is a 22-kDa protein that is expressed in various tissues and organs, including brain, heart, muscle, and pancreas. Its function is not well understood, but studies have shown that it plays a role in several cellular processes, including cell signaling, inflammation, and stress response.

One of the key features of SERTAD2 is its ability to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/Akt. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation. SERTAD2 has been shown to play a role in regulating these signaling pathways, and its dysfunction has been linked to several diseases.

SERTAD2 has also been shown to be involved in inflammation. Studies have shown that SERTAD2 is involved in the regulation of inflammatory responses, including the production of pro-inflammatory cytokines. This suggests that SERTAD2 may have potential as a therapeutic agent for reducing inflammation in various diseases.

In addition to its potential role in inflammation, SERTAD2 has also been shown to be involved in cell signaling. Studies have shown that SERTAD2 plays a role in regulating cell signaling pathways, including the production of neurotransmitters, such as dopamine and GABA. This suggests that SERTAD2 may have potential as a therapeutic agent for treating neurodegenerative diseases.

SERTAD2 has also been shown to be involved in stress response. Studies have shown that SERTAD2 plays a role in regulating stress responses, including the production of stress hormones, such as cortisol and adrenaline. This suggests that SERTAD2 may have potential as a therapeutic agent for treating stress-related disorders.

In conclusion, SERTAD2 is a protein that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a significant amount of research in recent years. Further studies are needed to fully understand its function and potential as a therapeutic agent.

Protein Name: SERTA Domain Containing 2

Functions: Acts at E2F-responsive promoters as coregulator to integrate signals provided by PHD- and/or bromodomain-containing transcription factors. May act as coactivator as well as corepressor of E2F1-TFDP1 and E2F4-TFDP1 complexes on E2F consensus binding sites, which would activate or inhibit E2F-target genes expression. Modulates fat storage by down-regulating the expression of key genes involved in adipocyte lipolysis, thermogenesis and oxidative metabolism

The "SERTAD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERTAD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets